- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04842890
Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer
This is a single arm phase II study of image-guided pencil beam scanning proton SBRT (40Gy RBE in 5 fractions delivered every other day) for patients with low- and intermediate-risk prostate cancer. The primary aim is to assess GU/GI toxicity of proton SBRT and compare this to historic outcomes associated with photon-based prostate SBRT. The primary endpoint is 2-year grade 3+ GU/GI toxicity free rate by CTCAE v5.0, which is expected to be ≥95%. Toxicity will be evaluated by the treating radiation oncologist at least once during SBRT, then following SBRT at 1, 3, 6, 12, 18, and 24 months. The treatment will be considered safe if grade 3 or higher GU/GI toxicity free rate at 2 years is >85% (95% rate expected with a 10% non-inferiority margin). The accrual goal is 61 patients over 3 years. To ensure that unexpected significant toxicity is identified, all grade 3 or higher toxicities will be reported to the study PI and the trial will stop accruing if at any point 4 or more patients experience a grade 3 or higher toxicity after completing SBRT. This is felt to be conservative given the vast experience with photon SBRT at this dose with an expected G3+ toxicity of ~5%.
Secondary objectives are to examine patient-reported urinary, gastrointestinal, sexual, and financial outcomes using IPSS, EPIC-26, and COST questionnaires at the same follow-up timepoints as above. Baseline measures of these domains will be obtained prior to treatment as well. Clinical outcomes will also be evaluated with PSA measured at each follow-up, as well as prostate MRI and biopsies at 2 years. Patients will be followed for at least 2 years to determine rates of PSA relapse, salvage treatment, development of metastases, death from prostate cancer, and overall survival. A dosimetric comparison will be performed where each patient will be planned for proton and photon SBRT to determine possible advantages of proton SBRT.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ryan Holder, BS
- Phone Number: 387 646-968-9055
- Email: research@nyproton.com
Study Locations
-
-
New York
-
New York, New York, United States, 10035
- Recruiting
- The New York Proton Center
-
Contact:
- Isabelle Choi, MD
- Phone Number: 303 646-968-9031
- Email: ichoi@nyproton.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Biopsy-proven NCCN low- or intermediate-risk prostate cancer, which includes patients with:
- Gleason score ≤7 disease
- PSA ≤20 ng/ml
Clinical T1-T2c disease
- Note: Patients who only have radiographic evidence of possible or probable T3 disease (i.e., extracapsular extension or seminal vesical invasion) will not be excluded.
- KPS ≥ 80%
- Prostate size as determined on MRI to be < 100 cc. Prostate size can be determined on CT scan if MRI is not available.
- Male 18 years of age or older
- IPSS ≤ 20
- Patient must be a candidate for and agree to placement of intraprostatic fiducial markers and a hydrogel rectal spacer
- Patient must be available for at least 2 years of follow-up
Exclusion Criteria:
Prior prostate surgery (including cryosurgery)
- Note: Patients who underwent TURP or greenlight PVP are eligible if it was > 12 weeks prior to the anticipated start date of SBRT
- Prior history of chronic prostatitis or urethral stricture
- Currently active cancer(s) other than non-melanoma skin cancers. Patients are not considered to have currently active cancers if they have completed therapy and are considered by their physicians to be at <5% risk of relapse within 2 years.
- Life expectancy of < 2 years
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Stereotactic body radiation therapy (SBRT) with Pencil Beam Scanning (PBS) proton therapy
|
The intervention being investigated is ultra-hypofractionated, image-guided, pencil beam scanning proton SBRT directed at the prostate gland and seminal vesicles to 40 Gy equivalent in 5 fractions, delivered every other day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1. Grade 3+ GU/GI toxicity-free rate determined by CTCAE v5.0 grading.
Time Frame: 2 years
|
The NCI Common Terminology Criteria for Adverse Events v5.0 is a descriptive terminology which can be utilized for Adverse Event (AE) reporting.
A grading (severity) scale is provided for each AE term.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1. Patient reported urinary symptoms determined by IPSS.
Time Frame: 2 years
|
The International Prostate Symptom Score (IPSS) was developed to assess the severity of lower urinary tract symptoms associated to Benign Prostatic Hyperplasia and has also been applied to other conditions that cause LUTS.
The IPSS consists of a total of seven questions that deal with voiding symptoms (incomplete empty, intermittency, weak stream and straining to void) and storage symptoms (frequency, urgency and nocturia) and an additional question to measure quality of life.
The score ranges from 0 to 35, with lower scores denoting a better health state.
|
2 years
|
2. Patient reported urinary, bowel, and hormonal quality of life determined by EPIC-26.
Time Frame: 2 years
|
EPIC-26 is the "Expanded Prostate Cancer Index Composite" patient reported outcomes questionnaire.
A clinical tool to assess urinary, bowel, sexual and vitality health.
The score from each of the 5 domains runs from 0 (none) to 12 (severe) impact on quality of life.
Each domain score when added together gives an overall score of zero (unaffected) to 60 (severely affected)
|
2 years
|
3. Patient reported financial toxicity determined by COST
Time Frame: 2 years
|
Comprehensive Score for Financial Toxicity Functional Assessment of Chronic Illness Therapy (COST-FACIT) was developed as part of a series of questionnaires aimed at measuring different symptom indexes of health-related quality of life in patients with advance disease such as cancer.
The survey contains 12 questions and each of them is rated from 0 (not at all) to 4 (very much).
This survey focuses on financial distress caused by illness in patients with cancer.
It takes about 5 minutes to complete.
|
2 years
|
4. 2-year and 5-year biochemical progression free survival
Time Frame: 2 years and 5 years
|
Biochemical failure is defined as a sustained rise in PSA of 2 ng/mL or more above the nadir (the lowest PSA level after radiotherapy).
|
2 years and 5 years
|
5. 2-year local control determined by MRI and biopsies
Time Frame: 2 years
|
2 years
|
|
6. 2-year and 5-year metastasis free survival
Time Frame: 2 years and 5 years
|
2 years and 5 years
|
|
7. 2-year and 5-year prostate cancer specific survival
Time Frame: 2 years and 5 years
|
2 years and 5 years
|
|
8. 2-year and 5-year overall survival
Time Frame: 2 years and 5 years
|
2 years and 5 years
|
|
9. Dosimetric advantages determined by target coverage, conformality, and normal tissue sparing
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Daniel Gorovets, MD, The New York Proton Center
- Principal Investigator: Shaakir Hasan, DO, The New York Proton Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NYPC ERC# 2020-027
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingProstate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
Clinical Trials on Pencil Beam Scanning Proton SBRT
-
Children's Hospital of PhiladelphiaRecruiting
-
Sidney Kimmel Comprehensive Cancer Center at Johns...RecruitingMelanoma | SarcomaUnited States
-
Thompson Cancer Survival CenterRecruitingBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage IIIUnited States
-
Abramson Cancer Center at Penn MedicineRecruitingCervical Cancer | Uterine CancerUnited States
-
Thompson Cancer Survival CenterRecruitingProstate Cancer | Prostate Adenocarcinoma | Prostate CarcinomaUnited States
-
Washington University School of MedicineRecruitingRecurrent Rectal CancerUnited States
-
The New York Proton CenterRecruitingBreast Cancer | Head and Neck Cancer | Gynecologic Cancer | Prostate Cancer | Thoracic Cancer | CNS Cancer | GI CancerUnited States
-
University of AarhusRecruitingAnal Cancer | Recurrent Anal CancerDenmark
-
University of AarhusRecruitingRectal Cancer RecurrentDenmark
-
Massachusetts General HospitalNational Cancer Institute (NCI)TerminatedNon-small Cell Lung CancerUnited States